Literature DB >> 16106403

Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo.

Shunro Uchinokura1, Shiro Miyata, Tsuyoshi Fukushima, Hiroshi Itoh, Shinichi Nakano, Shinichiro Wakisaka, Hiroaki Kataoka.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional growth factor that is involved in invasive growth of tumor cells via its receptor MET, a protein product of c-met proto-oncogene. HGF activator (HGFA) is a serine proteinase responsible for the activation of proform of HGF/SF (proHGF/SF). In our study, we examined the effects of engineered expression of HGFA on 2 human glioblastoma cell lines (YKG-1 and U251). Both cells expressed MET, while only YKG-1 expressed endogenous proHGF/SF. Enhanced MET phosphorylation and increased migratory activity were induced by the expression of HGFA in YKG-1 cells in vitro in the presence of thrombin, which is a known activator of proHGFA. In contrast, MET phosphorylation was consistently observed in U251 that lacked endogenous HGF/SF, suggesting ligand-independent activation of MET in this cell line. Consequently, the expression of HGFA in U251 did not enhance the MET phosphorylation and following cellular response even with the thrombin treatment. However, addition of exogenous proHGF/SF resulted in enhanced migratory activity of HGFA-expressing U251 cells in the presence of thrombin in vitro. The engineered HGFA expression resulted in significantly enhanced tumor growth with increased vascular density in vivo when YKG-1 cells were implanted in nude mouse brain. This effect was not observed in U251 lacking endogenous proHGF/SF. These results indicate the possible existence of multiple mechanisms of MET activation in glioblastomas and that the activation system of proHGF/SF is important in progression of glioblastomas that express endogenous proHGF/SF and require ligand-dependent MET activation. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16106403     DOI: 10.1002/ijc.21362

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Expression of hepatocyte growth factor activator inhibitor type 1 in endothelial cells.

Authors:  Yutaka Akiyama; Miyuki Nagai; Wataru Komaki; Kousuke Marutsuka; Yujiro Asada; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2006-08       Impact factor: 4.174

2.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 3.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.

Authors:  Fei Liu; Christopher D Cox; Reshmi Chowdhury; Laura Dovek; Huytram Nguyen; Tie Li; Sichen Li; Byram Ozer; Arthur Chou; Nhung Nguyen; Bowen Wei; Joseph Antonios; Horacio Soto; Harley Kornblum; Linda Liau; Robert Prins; P Leia Nghiemphu; William Yong; Timothy Cloughesy; Albert Lai
Journal:  J Neurooncol       Date:  2019-03-05       Impact factor: 4.130

5.  Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.

Authors:  Tsuyoshi Fukushima; Makiko Kawaguchi; Kenji Yorita; Hiroyuki Tanaka; Hideo Takeshima; Kazuo Umezawa; Hiroaki Kataoka
Journal:  Neuro Oncol       Date:  2011-10-03       Impact factor: 12.300

6.  The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme.

Authors:  O F Olmez; E Cubukcu; T Evrensel; M Kurt; N Avci; S Tolunay; A Bekar; A Deligonul; M Hartavi; N Alkis; O Manavoglu
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

7.  Structural insight into distinct mechanisms of protease inhibition by antibodies.

Authors:  Yan Wu; Charles Eigenbrot; Wei-Ching Liang; Scott Stawicki; Steven Shia; Bin Fan; Rajkumar Ganesan; Michael T Lipari; Daniel Kirchhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-05       Impact factor: 11.205

8.  Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value.

Authors:  Roberto Garcia-Navarrete; Esperanza Garcia; Oscar Arrieta; Julio Sotelo
Journal:  J Neurooncol       Date:  2009-10-25       Impact factor: 4.130

9.  Roles of Kunitz domains in the anti-invasive effect of hepatocyte growth factor activator inhibitor type 1 in human glioblastoma cells.

Authors:  Shiro Miyata; Tsuyoshi Fukushima; Kazuyo Kohama; Hiroyuki Tanaka; Hideo Takeshima; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2007-11       Impact factor: 4.174

10.  C-MET overexpression and amplification in gliomas.

Authors:  Yoonjin Kwak; Seong-Ik Kim; Chul-Kee Park; Sun Ha Paek; Soon-Tae Lee; Sung-Hye Park
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.